Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Julian Olea et al.|Clinical Cancer Research|2023Cited by 13
Phase 1b/2 Study of Escalating Doses of the NEDD8 Activating Enzyme Inhibitor Pevonedistat Administered in Combination with Standard Induction Therapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myeloid LeukemiaCarissa M. Feliciano, Kevin R. Kelly, Jennifer S. Carew et al.|Blood|2023Cited by 0
Supplementary Table S4 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Julian Olea et al.|Unknown|2023Cited by 0
Supplementary Table S3 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Julian Olea et al.|Unknown|2023Cited by 0
Supplementary Figure S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Julian Olea et al.|Unknown|2023Cited by 0